Navigation Links
Gerresheimer has Passed the Turning Point
Date:10/15/2009

DUSSELDORF, Germany, October 15 /PRNewswire-FirstCall/ --

- Nine-Month Sales (Excluding Technical Plastics) 1.7% Down on Prior Year

- EBITDA Margin at High Level of 17.2%

- As Expected, Third Quarter Marked by Inventory Reductions by Large Customers

In the first nine months of the financial year (December 2008 - August 2009), Gerresheimer AG achieved sales of EUR 744.3m (prior year EUR 783.4m). Excluding the Technical Plastics business which has been sold, sales totaled EUR 714.9m, a reduction of 1.7% compared with the prior year. The corresponding operating margin (adjusted EBITDA) for the first three quarters continued on a high level at 17.9%. In Gerresheimer's key market of pharmaceutics, long-term demand is stable although some pharma customers have continued to reduce their inventory levels. The cosmetics sales which accounts for only 10% of total Group sales remained weak as expected. For the fourth quarter, Gerresheimer expects an increase in demand for pharma packaging and a slight recovery in the cosmetics business. It has accordingly quantified more precisely the outlook for the full financial year 2009. Organic growth in the fourth quarter will be offset by the weak dollar exchange rate. For the full year a small sales decline of between 1.5% and 2.5% and an operating margin (adjusted EBITDA) of around 18.5% are expected.

"The trend in the pharma business continues to be characterized by long-term growth. We are successfully pushing ahead with the consistent orientation of the Gerresheimer Group as a leading global partner for the pharma industry," says Dr. Axel Herberg, CEO of Gerresheimer AG. "Our latest investments - particularly in the growth market of pharma plastics - reflect this."

The importance of the Plastic Systems Division, which grew by over 5% at constant exchange rates during the first three quarters, is also shown by the two recen
'/>"/>

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Scientists Reveal Roadmap to Brain Health That Can Be Passed Down to Future Generations: Exercise, Omega-3, Folic Acid, Vitamin B6, and Vitamin B12
2. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
6. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
7. AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
10. West Pharmaceutical Services, Inc. Appoints New Director
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... A report released,today by The Cornucopia Institute ... formula are seriously endangering the health of,some formula-fed ... Human Breast Milk in the,Laboratory, details research questioning ... produced in laboratories and extracted from,algae and fungus, ...
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
Cached Medicine Technology:Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 2Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) ... September, where issues related to claims involving the pain ... Pennsylvania, Bernstein Liebhard LLP reports. , According to ... website, the meeting is scheduled to take place on ... latest of several Tylenol conferences that have taken place ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many ... suppliers carefully, Top10BestSEOHosting.com is here to announce that ... hosting suppliers in 2014. , JustHost ( http://www.justhost.com/track/seohosts ... top-of-the-line shared hosting plan. The company’s approach to ... is affordable, accessible and powerful enough for anyone ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
(Date:9/1/2014)... CA (PRWEB) September 01, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... The US FDA announced on August 28, that specific ... recalled (Class I) as the device may reverse ... DePuy Synthes Craniomaxillofacial (CMF) Distraction System is an implant ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3
... but not frequency, study suggests , , THURSDAY, April ... 2-year-olds relate to each other affects the quality -- ... "terrible twos." And a child,s temperament plays a role ... to a new study. , Interactions between 60 mothers ...
... 3, 2008 With spring here and,summer fast approaching, ... said, attractive feet are a MUST!, YogaToes(R) are ... feel great. YogaToes(R) beautify feet with passive exercise that,helps ... by tight,shoes, high heels and overexertion., "Women aren,t ...
... MedQuist,Inc. (Pink Sheets: MEDQ.PK) announces that ... hospital in Newburyport, Mass., has selected MedQuist,Technology ... solution,including dictation, transcription and speech recognition. Anna ... and is home to a,nationally recognized Wound ...
... Third Bank,today announced a strategic alliance with GHN-Online ... cycle management services to,the healthcare industry, that will ... healthcare providers. The alliance,will enable Fifth Third Bank ... to payments -- and integrate the data into ...
... Expands Global Product Potential, LEXINGTON, Mass., April ... ) today announced the signing of a,License, Supply ... rights to market VANTAS(R) (histrelin acetate subcutaneous,implant) throughout ... is a,12-month implant for the treatment of advanced ...
... a child for a lifetime, researchers say, , , THURSDAY, April ... United States were victims of maltreatment in 2006 during their ... or neglect during their first week of life, federal officials ... examination of the risk for nonfatal maltreatment of children less ...
Cached Medicine News:Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:New Ten-Minute Foot Exercisers Beautify Feet for Spring and Summer Sandal Season 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 3Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 2Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 2Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 4Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3
2.5mm...
... 12 bevel tip; silicone sleeve ... is opposite curve, Designed for ... Sleeve acts as stop & ... chance of trauma to the ...
Stab incision blades color coded for simple and accurate identification...
Formed 12.0mm from bend to tip; radius is 12.5 mm;, Curved sharp cutting edge requires less pressure to cut the capsule, reducing stress to zonules. 1.5mm long x .75 mm wide...
Medicine Products: